查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2020552

2026-2034年全球活性药物成分（API）市场规模、份额、趋势和成长分析报告

Global Active Pharmaceutical Ingredients API Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 251 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

活性药物成分（API）的市场规模预计将从 2025 年的 2,813 亿美元成长到 2034 年的 4,801.2 亿美元，2026 年至 2034 年的复合年增长率为 6.12%。

全球对药品和医疗产品的需求不断增长，正推动全球活性药物成分（API）市场显着扩张。 API是药物中具有生物活性的成分，能够发挥所需的治疗效果。它们是生产多种药物（包括抗生素、止痛药和慢性病治疗药物）的必需原料。

原料药市场的主要驱动力是糖尿病、癌症和心血管疾病等慢性病的盛行率上升。对学名药需求的成长也促进了全球原料药产量的扩张。製药公司正投资先进的生产技术，以提高生产效率并确保高品质的药物研发。

随着全球医疗保健需求持续成长，原料药市场预计将稳定发展。新兴市场製药生产设施的扩张以及研发活动的活性化将支撑市场成长。此外，生物技术和个人化医疗的创新有望为原料药产业带来新的机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球活性药物成分（API）市场：依分子类型划分

  • 市场分析、洞察与预测
  • 乙酰胺酚
  • 萘普生
  • Furosemide
  • 呋喃妥因
  • 磺胺多辛
  • 乙胺嘧啶
  • 阿摩迪亚金
  • 阿扎那韦硫酸盐
  • 尼姆斯利德
  • Ciprofloxacin
  • 哌拉喹磷酸盐，索他洛尔
  • 左乙拉西坦
  • 双氯芬酸钠
  • 阿奇霉素
  • 其他的

第五章 全球活性药物成分（API）市场：依生产类型划分

  • 市场分析、洞察与预测
  • 内部生产
  • 外包

第六章 全球活性药物成分（API）市场：依产品类型划分

  • 市场分析、洞察与预测
  • 低活跃度 API
  • 高活动 API

第七章 全球医药活性成分（API）市场：依API类型划分

  • 市场分析、洞察与预测
  • 合成
  • 自然的

第八章 全球活性药物成分（API）市场：依规模划分

  • 市场分析、洞察与预测
  • 飞行员
  • 大规模

第九章 全球活性药物成分（API）市场：按应用划分

  • 市场分析、洞察与预测
  • 商业的
  • 研究

第十章 全球活性药物成分（API）市场：按最终用户划分

  • 市场分析、洞察与预测
  • 製药公司
  • 生技公司
  • 契约製造公司（CMO）
  • 其他的

第十一章 全球活性药物成分（API）市场：按地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十二章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十三章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc
    • Mangalam Drugs & Organics Limited
    • Viatris Inc
    • Lonza
    • Piramal Pharma Solutions
    • HISUN USA Inc
    • Ipca Laboratories Ltd
    • AbbVie Inc
    • Alembic Pharmaceuticals Limited
    • Biocon
    • Merck KGaA
    • Boehringer Ingelheim
    • Cambrex Corporation
    • Dr. Reddy's Laboratories Ltd
简介目录
Product Code: VMR112116214

The Active Pharmaceutical Ingredients API Market size is expected to reach USD 480.12 Billion in 2034 from USD 281.30 Billion (2025) growing at a CAGR of 6.12% during 2026-2034.

The global active pharmaceutical ingredients (API) market is expanding significantly due to the rising demand for pharmaceutical drugs and medical treatments worldwide. APIs are the biologically active components in medications that produce the desired therapeutic effects. They are essential for the manufacturing of a wide range of pharmaceutical products, including antibiotics, pain relievers, and treatments for chronic diseases.

A key driver of the API market is the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions. The growing demand for generic medicines is also contributing to the expansion of API production globally. Pharmaceutical companies are investing in advanced manufacturing technologies to improve production efficiency and ensure high-quality drug development.

In the future, the API market is expected to grow steadily as global healthcare demand continues to rise. The expansion of pharmaceutical manufacturing facilities in emerging economies and increased research and development activities will support market growth. Additionally, innovations in biotechnology and personalized medicine are expected to create new opportunities in the API industry.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Molecule Type

  • Acetaminophen
  • Naproxen
  • Furosemide
  • Nitrofurantoin
  • Sulfadoxine
  • Pyrimethamine
  • Amodiaquine
  • Atazanavir Sulfate
  • Nimesulide
  • Ciprofloxacin
  • Piperaquine Phosphate Sotalol
  • Levetiracetam
  • Diclofenac
  • Azithromycin
  • Others

By Production Type

  • Captive/In House
  • Outsourcing

By Product Type

  • Low Potent API
  • High Potent API

By API Type

  • Synthetic
  • Natural

By Scale

  • Pilot
  • Large

By Application

  • Commercial
  • Research

By End User

  • Pharmaceutical Companies
  • Biotechnological Companies
  • Contract Manufacturing Organizations (CMOs)
  • Others

COMPANIES PROFILED

  • Teva Pharmaceutical Industries Ltd, Pfizer Inc, Mangalam Drugs Organics Limited, Viatris Inc, Lonza, Piramal Pharma Solutions, HISUN USA Inc, Ipca Laboratories Ltd, AbbVie Inc, Alembic Pharmaceuticals Limited, Biocon, Merck KGaA, Boehringer Ingelheim, Cambrex Corporation, Dr Reddys Laboratories Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY MOLECULE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Molecule Type
  • 4.2. Acetaminophen Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Naproxen Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Furosemide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Nitrofurantoin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Sulfadoxine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Pyrimethamine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.8. Amodiaquine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.9. Atazanavir Sulfate Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.10. Nimesulide Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.11. Ciprofloxacin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.12. Piperaquine Phosphate Sotalol Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.13. Levetiracetam Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.14. Diclofenac Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.15. Azithromycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.16. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY PRODUCTION TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Production Type
  • 5.2. Captive/In House Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Outsourcing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Product Type
  • 6.2. Low Potent API Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. High Potent API Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY API TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Api Type
  • 7.2. Synthetic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Natural Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY SCALE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Scale
  • 8.2. Pilot Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Large Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast Application
  • 9.2. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY END USER 2022-2034 (USD MN)

  • 10.1. Market Analysis, Insights and Forecast End User
  • 10.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.3. Biotechnological Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.4. Contract Manufacturing Organizations (CMOs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API MARKET: BY REGION 2022-2034 (USD MN)

  • 11.1. Regional Outlook
  • 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.2.1 By Molecule Type
    • 11.2.2 By Production Type
    • 11.2.3 By Product Type
    • 11.2.4 By Api Type
    • 11.2.5 By Scale
    • 11.2.6 By Application
    • 11.2.7 By End User
    • 11.2.8 United States
    • 11.2.9 Canada
    • 11.2.10 Mexico
  • 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.3.1 By Molecule Type
    • 11.3.2 By Production Type
    • 11.3.3 By Product Type
    • 11.3.4 By Api Type
    • 11.3.5 By Scale
    • 11.3.6 By Application
    • 11.3.7 By End User
    • 11.3.8 United Kingdom
    • 11.3.9 France
    • 11.3.10 Germany
    • 11.3.11 Italy
    • 11.3.12 Russia
    • 11.3.13 Rest Of Europe
  • 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.4.1 By Molecule Type
    • 11.4.2 By Production Type
    • 11.4.3 By Product Type
    • 11.4.4 By Api Type
    • 11.4.5 By Scale
    • 11.4.6 By Application
    • 11.4.7 By End User
    • 11.4.8 India
    • 11.4.9 Japan
    • 11.4.10 South Korea
    • 11.4.11 Australia
    • 11.4.12 South East Asia
    • 11.4.13 Rest Of Asia Pacific
  • 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.5.1 By Molecule Type
    • 11.5.2 By Production Type
    • 11.5.3 By Product Type
    • 11.5.4 By Api Type
    • 11.5.5 By Scale
    • 11.5.6 By Application
    • 11.5.7 By End User
    • 11.5.8 Brazil
    • 11.5.9 Argentina
    • 11.5.10 Peru
    • 11.5.11 Chile
    • 11.5.12 Rest of Latin America
  • 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 11.6.1 By Molecule Type
    • 11.6.2 By Production Type
    • 11.6.3 By Product Type
    • 11.6.4 By Api Type
    • 11.6.5 By Scale
    • 11.6.6 By Application
    • 11.6.7 By End User
    • 11.6.8 Saudi Arabia
    • 11.6.9 UAE
    • 11.6.10 Israel
    • 11.6.11 South Africa
    • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

  • 12.1. Recent Developments
  • 12.2. Company Categorization
  • 12.3. Supply Chain & Channel Partners (based on availability)
  • 12.4. Market Share & Positioning Analysis (based on availability)
  • 12.5. Vendor Landscape (based on availability)
  • 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS API INDUSTRY

  • 13.1. Top Companies Market Share Analysis
  • 13.2. Company Profiles
    • 13.2.1 Teva Pharmaceutical Industries Ltd
    • 13.2.2 Pfizer Inc
    • 13.2.3 Mangalam Drugs & Organics Limited
    • 13.2.4 Viatris Inc
    • 13.2.5 Lonza
    • 13.2.6 Piramal Pharma Solutions
    • 13.2.7 HISUN USA Inc
    • 13.2.8 Ipca Laboratories Ltd
    • 13.2.9 AbbVie Inc
    • 13.2.10 Alembic Pharmaceuticals Limited
    • 13.2.11 Biocon
    • 13.2.12 Merck KGaA
    • 13.2.13 Boehringer Ingelheim
    • 13.2.14 Cambrex Corporation
    • 13.2.15 Dr. Reddy's Laboratories Ltd